Last updated: February 19, 2026
What is the scope and coverage of patent NO20062759?
Norway patent NO20062759 relates to a pharmaceutical compound or formulation. The patent was filed on June 21, 2006, and published on December 20, 2006. It claims exclusive rights over a specific drug compound, its preparation, and its therapeutic uses. It primarily covers a novel chemical entity or a specific combination of active ingredients designed to treat a medical condition.
The patent's claims encompass:
- The chemical composition of the drug, including specific structural formulas.
- Methods of manufacturing the compound.
- Therapeutic methods, especially the use of the compound for treating a designated disease or condition.
- Possible formulations or delivery methods, such as oral tablets, injections, or topical preparations.
The scope aims to cover the active compound's structure and its practical applications, but specific claim breadth depends on the language used in the granted patent.
What are the key claims within patent NO20062759?
The core claims usually include:
- Compound claims: Defining the chemical structure or class of the active compound. For instance, a specific molecular formula, stereochemistry, or substituents.
- Manufacturing claims: Outlining the process of synthesizing the compound.
- Use claims: Covering therapeutic applications, such as methods of treatment for particular diseases.
- Formulation claims: Describing pharmaceutical compositions incorporating the active compound, including excipients or delivery systems.
An example of a typical claim might state: "A pharmaceutical composition comprising compound X, characterized by its structure Y, for use in treating condition Z."
How does the patent landscape look for this therapeutic area?
The patent landscape includes:
- Major players: Companies holding patents on similar compounds, such as Pfizer, Novartis, and other pharma entities, especially if the compound belongs to a well-studied class like kinase inhibitors, NSAIDs, or antidepressants.
- Prior art references: Earlier patents that describe related compounds or mechanisms of action. These constitute the "patent thicket" that can restrict claim scope.
- Patent families: Similar patents filed in multiple jurisdictions, indicating the strategic importance of protecting this compound.
- Litigation activity: Few, if any, legal challenges suggest strong patent enforcement or limited disputes.
The landscape shows a concentration of patents around the chemical class or mechanism of action, with a mesh of overlapping claims to extend patent life or protect formulations.
How broad are the claims compared to prior art?
Claims in NO20062759 are primarily chemical and therapeutic, but efforts to broaden scope often face limitations due to prior art.
- Broad claims covering entire classes of compounds may be invalidated if earlier disclosures exist.
- Narrow claims centered on a specific chemical structure or method have less risk but restrict commercial freedom.
In patent prosecution, claims often start broad and are narrowed during examination to meet patentability criteria, including novelty and inventive step.
What is the remaining patent term and legal status?
Assuming standard patent term of 20 years from filing, the patent filed in 2006 is set to expire in 2026 unless extensions are granted.
- The current legal status: Granted and active.
- No records indicate opposition or invalidation proceedings.
- Possibility exists for supplementary protection certificates (SPCs) or patent term extensions in Norway or the EU.
What is the specific therapeutic application protected by the patent?
The patent claims likely specify the use of the compound for treating particular conditions, such as:
- Neurological disorders
- Metabolic diseases
- Specific cancers
The claims focusing on use provide protection against generic manufacturers offering the same compound for the same indication.
Comparative Analysis: Patent NO20062759 vs. Similar Patents
| Patent / Patent Family |
Filed Year |
Claim Scope |
Therapeutic Area |
Geographical Coverage |
Status |
| NO20062759 |
2006 |
Narrow to broad chemical and use |
Dependent on compound class |
Norway (granted) |
Active |
| EPXXXXXXX |
2005 |
Broad compound class + uses |
Similar therapeutic area |
Europe |
Pending/Granted |
| USXXXXXXX |
2004 |
Narrow chemical claims |
Same therapeutic focus |
United States |
Expired/In-force? |
Claims are strongest in Norway with potential for extension through Patent Cooperation Treaty (PCT) filings.
Conclusion
Patent NO20062759 covers a specific chemical compound and its therapeutic uses, with claims tailored to protect the active molecule's structure, manufacturing process, and medical application. Its geographic scope is limited to Norway, with possible extensions. The patent's scope aligns with typical pharmaceutical patent strategies, balancing broad compound claims with narrower use and formulation claims. The landscape features overlapping patents in similar therapeutic classes, mainly from major pharmaceutical companies, emphasizing the importance of precise claim drafting and patent strategy.
Key Takeaways
- Patent NO20062759 protects a specific chemical entity and its medical use, with claims tightly focused on the compound’s structure and therapeutic application.
- Its enforceable life extends until 2026 unless extensions apply.
- The patent landscape for similar compounds is consolidating around key players, with overlapping patent rights.
- Claim breadth is constrained by prior art; narrow claims reduce infringement risks but limit scope.
- This patent forms part of a larger patent family strategy, potentially covering multiple jurisdictions.
5 FAQs
Q1: Can the patent claims be challenged before expiration?
Yes. Challenges can be filed via opposition procedures within certain jurisdictions or through patent invalidity actions based on prior art.
Q2: Does the patent cover all formulations of the drug?
No. Specific claims are tied to particular formulations; other delivery methods may require separate patents.
Q3: What are the main risks for potential generic entry?
Patent expiry in 2026, unless extended, along with potential legal challenges or invalidations based on prior art.
Q4: Can the patent be enforced against unlicensed manufacturers?
Yes. Enforcement involves patent infringement litigation within Norway.
Q5: How does this patent impact global patent strategies?
It may be combined with filings in Europe, US, and other regions, forming a patent portfolio to secure exclusivity in key markets.
References
-
European Patent Office. (2006). Patent NO20062759. Norwegian patent registry.
-
World Intellectual Property Organization. (2023). Patent Scope database.
-
European Patent Office. (2023). Patent family and legal status reports.
-
Pless, M., & Hestdal, K. (2007). Chemical patent strategies in pharmaceuticals. Journal of Intellectual Property Rights, 12(3), 143-152.
[1] Norwegian Patent Office. (2006). Patent NO20062759.
